Genetic Polymorphisms in Aquaporin 1 as Risk Factors for Malignant Mesothelioma and Biomarkers of Response to Cisplatin Treatment

Radiology and Oncology - Germany
doi 10.2478/raon-2019-0009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Walter de Gruyter GmbH

Related search

Genetic Polymorphisms and Ovarian Cancer Risk and Response to Paclitaxel/Cisplatin Chemotherapy

Hereditary Cancer in Clinical Practice
OncologyGenetics
2015English

MicroRNAs as Potential Biomarkers in Malignant Pleural Mesothelioma

Current Biomarker Findings
BiochemistryClinical Biochemistry
2015English

Discovery of New Biomarkers for Malignant Mesothelioma

Current Pulmonology Reports
2015English

Genetic and Modifiable Risk Factors Contributing to Cisplatin-Induced Toxicities

Clinical Cancer Research
Cancer ResearchOncology
2018English

Cisplatin-Induced GADD34 Upregulation Potentiates Oncolytic Viral Therapy in the Treatment of Malignant Pleural Mesothelioma

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2006English

The Influence of Genetic Variability on the Risk of Developing Malignant Mesothelioma

Radiology and Oncology
Nuclear MedicineRadiologyImagingOncology
2018English

Enhanced Cisplatin Response With Histone Acetyl Transferase Inhibitor, Anacardic Acid, in Malignant Pleural Mesothelioma Cell Line

Turkiye Klinikleri Journal of Medical Sciences
Medicine
2013English

Multimodality Treatment of Malignant Pleural Mesothelioma

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2018English

A Retrospective Study of Palliative Cisplatin-Based Doublet Chemotherapy for Malignant Pleural Mesothelioma

Cancer and Clinical Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy